Shows
OIS Podcast | Ophthalmology's leading PodcastRoesky’s Quest: Durable Dry Eye TherapyIt started with a call. First, a call from Abbott led Christian Roesky to an industry role after completing his chemistry PhD in Germany. Next, came the call that would shape Roesky’s career—from Alcon, where he discovered eye care was his “everyday joy and passion.”The most pivotal call, however, came from Novaliq founder Bernhard Günther, who convinced Roesky to take his emerging startup to the next level. As managing director and CEO, Roesky has led Novaliq through development of a novel pipeline. Most notably, NOV03 (perfluorohexyloctane), a therapy des...2022-05-1837 min
OIS Podcast | Ophthalmology's leading PodcastFollow Your PassionThis week’s podcast guest is Christian Roesky, a chemist by training who found a passion for ophthalmology and spent the bulk of his career in management roles with B+L, Alcon and Abbott before taking the leap into the CEO position at Novaliq in 2016. Christian provides an insider view of Novaliq’s platform technology to address various ophthalmic indications and shares some words of wisdom for other innovators.2020-09-1629 min
OIS Podcast | Ophthalmology's leading PodcastNovaliq’s Positive Phase II Dry Eye Results Present Break from Disappointing Clinical Trial SeasonChristian Roesky, PhD, joins the OIS Podcast to explain why he became the new CEO and managing director of Novaliq GmbH, a specialty pharma company with a novel drug delivery platform technology that can make drugs more effective in treating ophthalmic disorders. He also delves into the company’s positive Phase II evaluating CyclASol in 207 patients with moderate-to-severe dry eye disease.2017-01-1224 min